Member Info for inanaco

0.04 of a mm

Just to give you an appreciation of SIZE of Cells imagine trying to extract the TCR element of a T cell

https://www.khanacademy.org/science/high-school-biology/hs-cells/hs-introduction-to-cells/v/scale-of-cells

you can actually see the HIV virus engaging a t cell

if it was so simple eh ! every one would do it.

ref eu

so we are looking for a cell mediated response

""" Cell-mediated immunity is an immune response that does not involve antibodies """

this generates the High avidity t cells

rather than

Antibody-Mediated Immunity. An intruding antigen is sensed by the B-cells in the lymph nodes and produce antibodies that bind to those antigens

so Scancell does not want a antibody response

Flu dont forget these are prophylactic vaccines designed to generate memory so this is called passive immunity

scancell vaccine are active vaccines which generate an adaptive immune response

"Ichor is pleased to partner with a global organization like Flextronics," said Ichor CEO, Bob Bernard. "Their dedication to quality and comprehensive solutions from design inputs to global distribution is a true asset to Ichor as we move toward rapid and scalable commercialization of the next generation TriGrid for novel DNA-based therapeutic products."

thought that meant they are signed up for a package

on the flextronics website the title is this

Flextronics Partners With Ichor Medical Systems To Provide Supply Chain Solutions, Including Design And Manufacturing Services

"supply chain solutions" i assumed that it was some sort of global service, as that is what they do

i think ichor is pretty poor at promotion, but then its private and really, it only needs to deal with the end user of the gun

Flextronics (Reg. No. 199002645H) is a leading end-to-end supply chain solutions company that delivers design, engineering, manufacturing and logistics services to a range of industries and end-markets, including data networking, telecom, enterprise computing and storage, industrial, capital equipment, appliances, automation, medical, automotive, aerospace and defense, energy, mobile, computing and other electronic product categories.Flextronics is an industry leader with $26 billion in sales, generated from helping customers design, build, ship, and service their products through an unparalleled network of facilities in approximately 30 countries and across four continents.

No, don't need to, the service deal is world wide, why would ichor build trigrid 2 with world wide service then supply trigrid 1

Yes they are using trigrid 2 location, is below so its not a US based trial

Korea, Republic of
The Catholic University of Korea Seoul St. Mary's Hospital Recruiting
Seoul, Korea, Republic of, 06591
Contact: Hae Hee-sook, CRC +82-2-2258-2724 prigia83@naver.com
Principal Investigator: Park Jong-Sup, M.D.
Sub-Investigator: Hur Soo-Young, M.D.
Korea University Guro Hospital Recruiting
Seoul, Korea, Republic of, 152-703
Contact: Lee Hye-Lim, CRC +82-2-2626-1206 hlna14@hanmail.net
Principal Investigator: Lee Jae-Kwan, M.D.
Sponsors and Collaborators
Genexine, Inc.
Merck Sharp & Dohme Corp.
Investigators
Principal Investigator: Jong-Sup Park, M.D The Catholic University of Korea

seems even bad has value ...

its better than PD-1 could mange on its own ... but again tiny numbers so only use it as an indicator

scib1 was the priming agent so not quite sure what your saying ..

it has been suggested TF

Up coming Combo trial, after some very careful reading I found this little nugget in the Research paper archives

, no patients received checkpoint inhibitors prior to vaccination
but six patients (four with tumor and two with no tumor
at study entry) received ipilimumab or nivolumab post-vaccination
and three of these patients are still alive. Although these
patient numbers are low, this suggests that SCIB1 vaccination
may prime for responses to checkpoint inhibition.

i know that is why i changed it

sorry Small cell SCLC

https://immuno-oncologynews.com/2018/08/21/immunotherapy-opdivo-fda-approved-some-small-cell-lung-cancer-patients/?utm_medium=desktop-push-notification&utm_source=Notifications&utm_campaign=OneSignal

Opdivo’s effectiveness was shown in 109 patients who received 3 mg/kg of Opdivo administered into the vein over one hour every two weeks. Patients received the treatment regardless of their PD-L1 expression level, and treatment was maintained until disease progression or unacceptable toxicity.
Chemo
Median duration of treatment was one month, with a range of zero to 44.2-plus months. Of the patients, 17% of the patients were treated for more than six months, and 9% for more than a year.

Tumor response to the therapy began six weeks after the first dose and was maintained for the first 5.5 months (24 weeks). After that, monitoring was performed every 12 weeks

what can i do if I only find reward ? how can I add risk to that model ?

some need to really think what "mitigating risk is "

its not about finding the reward

its about finding a flaw

All i can say Ruck is you have this wonderful life experience indeed its of such intensity that the other day you posted on intelligence

"" I suspect mine is higher than yours, although we couldn't establish that unless you divulged yours and I divulged mine.""

what i can confirm with my intelligence chips on shoulders are difficult to heal.